| Literature DB >> 35448082 |
Wei Joo Chen1, Arimi Fitri Mat Ludin2, Nor M F Farah1.
Abstract
Exaggerated cardiovascular reactivity to and delayed recovery from stress increase the risk of cardiovascular diseases in the future. While exercise training has been shown to attenuate stress-induced cardiovascular reactivity and enhance recovery from stress, the effects with acute exercise are less characterized. The aim of this scoping review was to explore the range and characteristics of published evidence regarding acute exercise on cardiovascular reactivity and stress recovery. The secondary objective was to highlight research gaps and implications for future research. A total of 36 articles met the review inclusion/exclusion criteria, involving 1200 participants from various age groups, fitness and health status. Blood pressure (BP) reactivity was the most measured outcome, followed by heart rate (HR) reactivity, and to some extent, heart rate variability. Overall, acute exercise particularly of the moderate-intensity aerobic type effectively reduced stress-induced BP reactivity in the general population. The effects on HR reactivity and cardiovascular recovery were inconclusive. Further research would be recommended to establish if other forms of exercise intensity or type are equally beneficial to lower exaggerated cardiovascular responses to stress. Despite methodological differences and limitations, the available evidence supports the therapeutic potential of acute exercise in addressing the ill effects of stress on cardiovascular health.Entities:
Keywords: HIIT; aerobic exercise; autonomic function; blood pressure; chronic stress; heart rate
Year: 2022 PMID: 35448082 PMCID: PMC9029480 DOI: 10.3390/jcdd9040106
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1PRISMA flow diagram showing identified, included and excluded studies.
Characteristics and outcomes of included studies.
| Author | Study Design | Participants | Age (Years) | Exercise | Stressor | Outcome Parameters | Main Findings | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Type | Intensity | Duration | Type | Time of Measurement | ||||||
| Aladro-Gonzalvo et al., 2019 [ | Crossover RCT | 25M | R: 12–15 | HIIE | Vigorous | 26 min | Social | 5 min post-exercise | SBP, DBP, HR, HRV | Better SBP and HR recovery with exercise. No changes to BP, HR and HRV reactivity. |
| Alderman et al., 2007 [ | Parallel RCT | 48M/42F | M: 22.9 ± 4.2 | ACE | (1) Moderate | 30 min | Cognitive | 5, 30 or 60 min post-exercise | SBP, DBP, HR | Lower SBP, DBP and HR reactivity, and better HR recovery after both exercises. DBP recovery improved only after vigorous-intensity ACE. Vigorous-intensity ACE has greater effect on SBP reactivity, HR reactivity and HR recovery. |
| Bartholomew 2000 [ | Parallel RCT | 17M/23F | M: 21.2 | ACE | Near-maximal to maximal | Not applicable | Cognitive (MA) Social (Stroop, Speech) | 40 min | MAP, HR | Lower MAP reactivity with exercise. No changes to HR reactivity. |
| Benvenutti et al., 2017 [ | Crossover RCT | 13M/11F | M: 22.9 ± 3.5 | FE | - | 30 min | Cognitive | Immediately post-exercise | SBP, DBP, HR, HRV | Better SBP and DBP recovery with exercise. No changes to SBP, DBP, HR and HRV reactivity. |
| Boone et al., 1993 [ | Crossover RCT | 8 (gender unknown) | M: 41.1 ± 6.5 | ACE | Moderate | 60 min | Cognitive (Stroop) | 10 min | SBP, DBP, MAP, HR | Lower SBP, DBP and MAP reactivity with exercise. No changes to HR reactivity. |
| Brownley et al., 2003 [ | Pre–post trial | 12M/12F | M: 24.5 ± 4.0 | ACE | Moderate | 25 min | Cognitive (MA) Social (Speech) | Pre- and 30 min post-exercise | SBP, DBP, MAP, HR | Lower SBP, DBP and MAP reactivity with exercise. No changes to HR reactivity. |
| Ebbesen et al., 1992 [ | Parallel RCT | 24M | R: 18–35 | ACE | Moderate | (1) 1 h | Physiological (CPT), Cognitive (Stroop), and Social (Speech) | 1, 3 and 24 h post-exercise | SBP, DBP, HR | Lower SBP reactivity with 1 h ACE. Lower DBP reactivity with both exercises. No changes to HR reactivity and recovery. |
| Farah et al., 2021 [ | Crossover RCT | 13M | M: 22.8 ± 2 | (1) HIIE | (1) Vigorous | (1) 20 min | Physiological (CPT) | 30 min | SBP, DBP, MAP, HR | Lower SBP, DBP, MAP reactivity with HIIE. Lower SBP reactivity reduced with ACE. No changes to BP recovery, HR reactivity and HR recovery. No differences between HIIE and ACE on SBP reactivity. |
| Gauche et al., 2017 [ | Pre–post trial | 10F | M: 71.1 ± 5.5 | (1) RE(t) | Moderate | Not applicable | Cognitive (Stroop) | Pre- and 60 min post-exercise | SBP, DBP, MAP, HRV | Lower SBP, DBP, MAP and HRV (In LF) reactivity with exercise. No differences between RE(t) and RE(c) on SBP, DBP and MAP reactivity. |
| Hamer et al., 2006 [ | Crossover RCT | 30M | M: | ACE | Vigorous | 20 min | Cognitive (Stroop) | 30 min | SBP, DBP, HR | Lower HR reactivity with exercise. No changes to SBP and DBP reactivity. |
| Heffernan et al., 2017 [ | Crossover RCT | 9M/6F | M: 26 ± 1 | RE | Light-to-moderate | 30 min | Physiological (CPT) | 30 min | SBP, DBP | Lower DBP reactivity with exercise. No changes to SBP reactivity, SBP recovery and DBP recovery. |
| Hobson and Rejeski 1993 [ | Parallel RCT | 80F | M: 18.3 ± 0.9 | ACE | Vigorous | (1) 10 min | Cognitive (Stroop) | 20 min | SBP, DBP, MAP, HR | Lower DBP and MAP reactivity with 40 min ACE. |
| Ketelhut et al., 2016 [ | Pre–post trial | 39M | M: 34 ± 8 | HIIE | Near-maximal to maximal | 30 min | Physiological (CPT) | Pre- and 60 min post-exercise | SBP, DBP | Lower SBP and DBP reactivity with exercise. |
| Meireles et al., 2020 [ | Crossover RCT | 22M | M: 23 ± 2 | (1) HIIE | (1) Vigorous | (1) 20 min | Physiological (CPT) | 30 min | SBP, DBP, HR, HRV | Lower HR reactivity after ACE. No changes to BP and HRV reactivity. No differences between HIIE and ACE on HR reactivity. |
| Messerli-Bürgy et al., 2019 [ | Parallel RCT | NW-con: 6M/7F | M: | ACE | Moderate | 30 min | Social | 15 min | SBP, DBP, HR | Better HR recovery with exercise. No changes to BP reactivity and recovery. |
| Monroe et al., 2018 [ | Crossover RCT | 9F | R: 20–33 | (1) FE | (1) Very light to light | 20 min | Physiological (CPT) | 20 min | SBP, DBP, HR | Better SBP and DBP recovery with both exercises. No changes to BP and HR reactivity. No differences between FE and ACE on BP recovery. |
| Moreira et al., 2014 [ | Crossover RCT | 10M/10F | M: 33.4 ± 6.9 | RE + ACE | Moderate-to-vigorous | Not | Physiological (CPT) | Pre- and 60 min post-exercise | SBP, DBP | Lower BP reactivity and better recovery with exercise. |
| Neves et al., 2012 [ | Crossover RCT | Con (subgroup): 2M/9F | M: | ACE | Near-maximal to maximal | ≈10 min | Cognitive (Stroop) | Pre- and 1 h | SBP, DBP, MAP, HR | Lower SBP reactivity with exercise. No changes to DBP, MAP and HR reactivity. |
| Paine et al., 2013 [ | Crossover RCT | 18M | M: 20.4 ± 1.2 | RE | Vigorous | Not | Cognitive (MA) | 6 h post-exercise | SBP, DBP, HR, RMSSD | No changes to BP, HR and HRV reactivity. |
| Probst et al., 1997 [ | Crossover RCT | 12M/12F | M: 23.3 ± 0.7 | ACE | Moderate | 30 min | Cognitive (Stroop), Physiological (CPT) | Pre- and 15 min post-exercise | SBP, DBP, MAP, HR | Lower SBP and HR reactivity with exercise. No changes to DBP and MAP reactivity. |
| Rejeski et al., 1991 [ | Crossover RCT | 12 (gender unknown) | M: 30.6 ± 1.5 | ACE | (1) Moderate | (1) 30 min | Cognitive (Stroop) | 30 min | SBP, DBP, MAP, HR | Lower DBP and MAP reactivity with both exercises. No changes to HR reactivity. Only vigorous-intensity ACE reduced SBP reactivity. Vigorous-intensity ACE has greater effect on SBP and MAP reactivity. |
| Rejeski et al., 1992 [ | Crossover RCT | 48F | R: 25–40 | ACE | Vigorous | 40 min | Cognitive (Stroop) | 30 min | SBP, DBP, MAP, HR | Lower SBP, DBP and MAP reactivity with exercise. No changes to HR reactivity. |
| Rejeski et al., 1995 [ | Parallel RCT | 8M/20F | M: | (1) ACE (walking) | (1) Moderate-to-vigorous | 40 min | Cognitive (MA) | 15 min | SBP, DBP, HR | No changes to SBP, DBP and HR reactivity. |
| Rocha et al., 2012 [ | Pre–post trial | GG: 3M/13F | R: 18–49 | ACE | Near-maximal to maximal | ≈10 min | Cognitive (Stroop) | Pre- and 60 min post-exercise | SBP, DBP, HR | Lower DBP and HR reactivity in GT/TT group. Only DBP reactivity lower in GG. No changes to SBP reactivity. |
| Roemmich et al., 2009 [ | exp1: Parallel RCT | Con: 7/7 | M: | HIIE | Vigorous | 20 min | Social | 20 min | SBP, DBP, HR | Lower DBP reactivity with exercise. No changes to SBP and HR reactivity. |
| Roemmich et al., 2009 [ | exp2: Crossover RCT | 11M/11F | M: 10.5 ± 1.4 | HIIE | Vigorous | 20 min | Social | 20 min | SBP, DBP, HR | Lower SBP, DBP and HR reactivity with exercise. |
| Rooks et al., 2011 [ | Crossover RCT | 24F | Smoker: | ACE | Moderate | 30 min | Physiological (CPT), Cognitive (Stroop) | Pre- and 10 min post-exercise | HR | No changes to HR reactivity. |
| Roth 1989 [ | Parallel RCT | 40M/40F | M: 20.8 ± 3.5 | ACE | Light-to-moderate | 20 min | Cognitive (Digits backward, MA) | Pre- and | SBP, DBP, HR | No changes to SBP, DBP and HR reactivity. Females had greater HR reactivity than males. |
| Roy and Steptoe 1991 [ | Parallel RCT | Con: 10M | M: | ACE | (1) Light | 20 min | Cognitive (MA) | 20 min | SBP, DBP, HR | Lower SBP, DBP and HR reactivity, better SBP, DBP and HR recovery with moderate-intensity ACE. Moderate-intensity ACE had greater effect on SBP recovery, HR reactivity and HR recovery. |
| Santaella et al., 2006 [ | Crossover RCT | NT: 8M/6F | M: 39 ± 2 | ACE | Moderate | 45 min | Cognitive (Stroop) | 80 min | SBP, DBP | Lower DBP reactivity with exercise. No changes to SBP reactivity. |
| Scott et al., 2008 [ | Crossover RCT | 10M | M: 29 ± 2 | (1) HIIE | Near-maximal to maximal and moderate | (1) 60 min | Physiological (LBNP) | 20 min | MAP, HR, HRV | No changes to MAP, HR and HRV reactivity and recovery. No differences between HIIE and ACE. |
| Someya et al., 2012 [ | Crossover RCT | 11M | M: 25 ± 5 | ACE | Moderate | 30 min | Cognitive (MA) | 15 min | SBP, DBP, MAP | No changes to SBP, DBP and MAP reactivity and recovery. |
| Steptoe et al., 1993 [ | Parallel RCT | 72M | R: 20–35 | ACE | (1) Moderate | 20 min | Cognitive (MA), Social (Speech) | 30 min | SBP, DBP, HR | Lower SBP reactivity and better SBP and DBP recovery with vigorous intensity. No changes to HR reactivity. |
| Taylor and Katomeri 2006 [ | Parallel RCT | Con: 15M/14F | M: | ACE | Very light | 15 min | Cognitive (Stroop) Social (Speech) | 10 min | SBP, DBP, MAP, HR | Lower SBP, DBP and MAP reactivity with exercise. No changes to HR reactivity. |
| Taylor and Oliver 2009 [ | Crossover RCT | 5M/25F | M: 25.3 ± 9.7 | ACE | Light | 15 min | Cognitive (Stroop,) | 10 min | SBP, DBP, MAP | Lower SBP, DBP and MAP reactivity with exercise. |
| Vianna et al., 2014 [ | Pre–post trial | 15M/19F | M: | ACE | Near-maximal to maximal | Not applicable | Cognitive (Stroop) | Pre- and 60 min post-exercise | MAP, HR | Lower MAP reactivity. No changes to HR reactivity. |
| West et al., 1998 [ | Crossover RCT | 14M/18F | M: 34 ± 8 | ACE | Moderate | 20 min | Physiological (CPT), Cognitive (MA) | 20 min | SBP, DBP, MAP | Lower DBP reactivity with exercise. No changes to SBP and MAP reactivity. |
ACE, aerobic continuous exercise; Con, control group; CPT, cold pressor task; DBP, diastolic blood pressure; Ex, exercise group; F, female; FH+, with family history of hypertension; FH−, without family history of hypertension; FE, flexibility exercise; GG, without 894G > T polymorphism in nitric oxide synthase; GT/TT, with 894G > T polymorphism in nitric oxide synthase; HIIE, high-intensity interval exercise; h, hour; HR, heart rate; HRV, heart rate variability; HT, hypertensive; LBNP, lower-body negative pressure; In LF, logarithmic normalization of low frequency; M (for age), mean; M (for gender), male; MA, Mental arithmetic task; MAP: mean arterial pressure; mins, minutes; NT, normotensive; NW, normal weight; OB, obese; OW, overweight; R, range; RCT, randomized control trial; RE, resistance exercise; RE(t), traditional resistance exercise; RE(c), circuit-based resistance exercise; RMSSD, root mean square of successive differences; SBP, systolic blood pressure; TSST-C, Trier Social Stress Test for children.
PRISMA-ScR Checklist.
| Section | Item | Prisma-Scr Checklist Item | Reported on Page |
|---|---|---|---|
|
| |||
| Title | 1 | Identify the report as a scoping review. | 1 |
|
| |||
| Structured summary | 2 | Provide a structured summary that includes (as applicable): background, objectives, eligibility criteria, sources of evidence, charting methods, results and conclusions that relate to the review questions and objectives. | 1 |
|
| |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. Explain why the review questions/objectives lend themselves to a scoping review approach. | 1–2 |
| Objectives | 4 | Provide an explicit statement of the questions and objectives being addressed with reference to their key elements (e.g., population or participants, concepts and context) or other relevant key elements used to conceptualize the review questions and/or objectives. | 2 |
|
| |||
| Protocol and registration | 5 | Indicate whether a review protocol exists; state if and where it can be accessed (e.g., a Web address); and if available, provide registration information, including the registration number. | - |
| Eligibility criteria | 6 | Specify characteristics of the sources of evidence used as eligibility criteria (e.g., years considered, language and publication status), and provide a rationale. | 3 |
| Information sources | 7 | Describe all information sources in the search (e.g., databases with dates of coverage and contact with authors to identify additional sources), as well as the date the most recent search was executed. | 3 |
| Search | 8 | Present the full electronic search strategy for at least 1 database, including any limits used, such that it could be repeated. | 3 |
| Selection of sources of evidence | 9 | State the process for selecting sources of evidence (i.e., screening and eligibility) included in the scoping review. | 3 |
| Data charting process | 10 | Describe the methods of charting data from the included sources of evidence (e.g., calibrated forms or forms that have been tested by the team before their use, and whether data charting was conducted independently or in duplicate) and any processes for obtaining and confirming data from investigators. | 3 |
| Data items | 11 | List and define all variables for which data were sought and any assumptions and simplifications made. | 2 |
| Critical appraisal of individual sources of evidence | 12 | If carried out, provide a rationale for conducting a critical appraisal of included sources of evidence; describe the methods used and how this information was used in any data synthesis (if appropriate). | - |
| Synthesis of results | 13 | Describe the methods of handling and summarizing the data that were charted. | 3 |
|
| |||
| Selection of sources of evidence | 14 | Give numbers of sources of evidence screened, assessed for eligibility and included in the review, with reasons for exclusions at each stage, ideally using a flow diagram. | 4 |
| Characteristics of sources of evidence | 15 | For each source of evidence, present characteristics for which data were charted and provide the citations. | 5–15 |
| Critical appraisal within sources of evidence | 16 | If carried out, present data on critical appraisal of included sources of evidence (see item 12). | - |
| Results of individual sources of evidence | 17 | For each included source of evidence, present the relevant data that were charted that relate to the review questions and objectives. | 16 |
| Synthesis of results | 18 | Summarize and/or present the charting results as they relate to the review questions and objectives. | 16–18 |
|
| |||
| Summary of evidence | 19 | Summarize the main results (including an overview of concepts, themes and types of evidence available), link to the review questions and objectives and consider the relevance to key groups. | 18–19 |
| Limitations | 20 | Discuss the limitations of the scoping review process. | 20 |
| Conclusions | 21 | Provide a general interpretation of the results with respect to the review questions and objectives, as well as potential implications and/or next steps. | 20 |
|
| |||
| Funding | 22 | Describe sources of funding for the included sources of evidence, as well as sources of funding for the scoping review. Describe the role of the funders of the scoping review. | 20 |